Sunshine Biopharma Approved to Market Anastrozole in Canada
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 25 2026
0mins
Sunshine Biopharma announced the approval of its generic Anastrozole tablets of 1mg for the Canadian market. Anastrozole is the generic equivalent of the brand name breast cancer drug, Arimidex. Anastrozole is a highly prescribed non-steroidal aromatase inhibitor. It works by lowering estrogen levels in the body to slow down or reverse the growth of specific breast tumors. Anastrozole is standard care for the adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer. Sunshine Biopharma has established a robust distribution network across Canada through its wholly owned Canadian subsidiary, Nora Pharma. The Company anticipates that its Anastrozole will be ready to ship to pharmacies before the end of 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SBFM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SBFM
About SBFM
Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Stocks Show Strong Pre-Market Moves
- Bluejay Diagnostics Surge: Bluejay Diagnostics, Inc. (BJDX) skyrocketed 193% to $6.35 in pre-market trading, indicating strong market demand for its products, which may attract more investor interest in its future developments.
- Picard Medical Significant Growth: Picard Medical, Inc. (PMI) saw a 95% increase to $0.33, reflecting positive investor sentiment towards its new products or services, potentially providing the company with additional funding support.
- Sunshine Biopharma Continues Upward Trend: Sunshine Biopharma, Inc. (SBFM) rose 26% to $3.00 in pre-market trading, suggesting optimistic market sentiment regarding its R&D progress, which could facilitate an expansion of its market share.
- Fulcrum Therapeutics Major Decline: Fulcrum Therapeutics, Inc. (FULC) plummeted 52% to $3.06 in pre-market trading, indicating investor concerns about its financial health, which may limit its ability to secure future financing.
See More
Sunshine Biopharma Shares Surge 66% After Reverse Split and Drug Approval
- Stock Surge: Sunshine Biopharma (SBFM) shares jumped 66% in pre-market trading on June 2, 2026, primarily due to the company's 1-for-10 reverse stock split effective June 1, 2026, indicating strong market optimism about its future prospects.
- Drug Approval: The company announced Canadian approval for its generic Rivaroxaban tablets in 2.5mg, 10mg, 15mg, and 20mg strengths, which is the generic equivalent of the anticoagulant Xarelto, widely used for treating deep vein thrombosis and pulmonary embolism, expected to significantly enhance the company's market share.
- Market Potential: The global market for Rivaroxaban is projected to reach $12.7 billion by 2026 and expand to approximately $30.5 billion by 2035, growing at a CAGR of 10.19%, providing Sunshine Biopharma with substantial growth opportunities, particularly in the Canadian market.
- Product Line Expansion: Sunshine Biopharma currently markets 60 generic drugs in Canada, with plans to launch 12 more in 2026; the CEO stated that this drug approval will further strengthen the company's position in the generics market, reflecting its commitment to delivering affordable medicines.
See More
Sunshine Biopharma Announces Reverse Stock Split
- Reverse Split Announcement: Sunshine Biopharma (SBFM) announced a one-for-ten reverse stock split effective June 1, 2026, aimed at regaining compliance with Nasdaq's minimum bid price requirement to ensure continued listing.
- Stock Price Decline: Following the announcement, SBFM's stock price fell by 13.7% to $0.37, reflecting market concerns about the company's future prospects, which could impact investor confidence.
- Share Reduction: The reverse split will reduce the company's issued and outstanding shares from 21.23 million to approximately 2.12 million, significantly lowering the market float and potentially affecting liquidity.
- Compliance Pressure: The reverse split is necessary to meet Nasdaq's minimum price requirements; failure to comply could lead to delisting risks, further impacting the company's ability to raise funds and operate effectively.
See More
Biotech Sector Regulatory Approvals and Collaborations
- Kidney Cancer Treatment Breakthrough: HUTCHMED and Innovent received NMPA approval in China for the ELUNATE-TYVYT combination therapy, supported by the FRUSICA-2 study showing a 63% reduction in disease progression or death risk, with a median progression-free survival of 22.2 months, significantly improving patient outcomes and enhancing market competitiveness.
- Antibiotic Market Expansion: Sunshine Biopharma received Canadian approval for its generic Amoxicillin, with shipments expected to begin in August 2026, aiming to increase access to high-quality antibiotics for treating common infections, which is anticipated to drive revenue growth for the company.
- Liquid Biopsy Technology Innovation: Guardant Health gained FDA approval for Guardant360 Liquid CDx, now the largest liquid biopsy panel with a genomic footprint 100 times broader than its predecessor, enhancing tumor profiling capabilities and expected to boost the company's market share in precision medicine.
- New Hypertension Drug Launch: AstraZeneca received FDA approval for BAXFENDY for hypertension patients, based on positive results from the BaxHTN Phase III trial, which is expected to strengthen the company's competitive position in the cardiovascular drug market and further expand its product line.
See More
Multiple Companies Experience Significant Stock Price Gains
- CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw a 55% increase in stock price, closing at $3.71, following the completion of its assay development strategy for the Bundibugyo virus, enhancing its market position in the Congo and Uganda.
- AKTX Breakthrough Clinical Data: Akari Therapeutics Plc (AKTX) rose nearly 50% to $5.14 after demonstrating synergistic activity of AKTX-101 with Adagrasib in KRAS-mutated pancreatic cancer models, with a Phase 1 clinical trial expected to start by mid-2027.
- P3 Health Financial Recovery: P3 Health Partners Inc. (PIII) gained over 40%, closing at $13.86, reporting a net income of $3 million for Q1, a significant turnaround from a $44.2 million loss last year, with full-year revenue projected between $1.5 billion and $1.65 billion.
- Sunshine Drug Approval: Sunshine Biopharma Inc. (SBFM) jumped over 40% to $0.51 after receiving approval for its generic Amoxicillin in Canada, expected to ship by August 2026, further expanding its market share.
See More
Sunshine Biopharma Raises $6 Million in Public Offering
- Financing Structure: Sunshine Biopharma has priced a public offering of 12 million common units at $0.50 each, raising a total of $6 million, with closing expected on May 19, 2026, thereby strengthening its cash position for future growth.
- Shareholder Rights: Each common unit consists of one share of common stock and two Series C warrants, which are exercisable immediately at $0.50 per share for five years, enhancing potential returns for investors.
- Market Performance: The company's stock surged 79.51% in yesterday's trading to close at $0.51, although it fell 5.57% in after-hours trading, reflecting a positive market reaction to the new financing amid short-term volatility.
- Product Expansion: Sunshine currently markets 60 generic prescription drugs in Canada and plans to launch 12 additional products in 2026, while also advancing two proprietary drug programs aimed at expanding its footprint in oncology and antiviral therapeutics.
See More
Biotech Stocks Show Strong Pre-Market Moves
- Bluejay Diagnostics Surge: Bluejay Diagnostics, Inc. (BJDX) skyrocketed 193% to $6.35 in pre-market trading, indicating strong market demand for its products, which may attract more investor interest in its future developments.
- Picard Medical Significant Growth: Picard Medical, Inc. (PMI) saw a 95% increase to $0.33, reflecting positive investor sentiment towards its new products or services, potentially providing the company with additional funding support.
- Sunshine Biopharma Continues Upward Trend: Sunshine Biopharma, Inc. (SBFM) rose 26% to $3.00 in pre-market trading, suggesting optimistic market sentiment regarding its R&D progress, which could facilitate an expansion of its market share.
- Fulcrum Therapeutics Major Decline: Fulcrum Therapeutics, Inc. (FULC) plummeted 52% to $3.06 in pre-market trading, indicating investor concerns about its financial health, which may limit its ability to secure future financing.
See More
Sunshine Biopharma Shares Surge 66% After Reverse Split and Drug Approval
- Stock Surge: Sunshine Biopharma (SBFM) shares jumped 66% in pre-market trading on June 2, 2026, primarily due to the company's 1-for-10 reverse stock split effective June 1, 2026, indicating strong market optimism about its future prospects.
- Drug Approval: The company announced Canadian approval for its generic Rivaroxaban tablets in 2.5mg, 10mg, 15mg, and 20mg strengths, which is the generic equivalent of the anticoagulant Xarelto, widely used for treating deep vein thrombosis and pulmonary embolism, expected to significantly enhance the company's market share.
- Market Potential: The global market for Rivaroxaban is projected to reach $12.7 billion by 2026 and expand to approximately $30.5 billion by 2035, growing at a CAGR of 10.19%, providing Sunshine Biopharma with substantial growth opportunities, particularly in the Canadian market.
- Product Line Expansion: Sunshine Biopharma currently markets 60 generic drugs in Canada, with plans to launch 12 more in 2026; the CEO stated that this drug approval will further strengthen the company's position in the generics market, reflecting its commitment to delivering affordable medicines.
See More
Sunshine Biopharma Announces Reverse Stock Split
- Reverse Split Announcement: Sunshine Biopharma (SBFM) announced a one-for-ten reverse stock split effective June 1, 2026, aimed at regaining compliance with Nasdaq's minimum bid price requirement to ensure continued listing.
- Stock Price Decline: Following the announcement, SBFM's stock price fell by 13.7% to $0.37, reflecting market concerns about the company's future prospects, which could impact investor confidence.
- Share Reduction: The reverse split will reduce the company's issued and outstanding shares from 21.23 million to approximately 2.12 million, significantly lowering the market float and potentially affecting liquidity.
- Compliance Pressure: The reverse split is necessary to meet Nasdaq's minimum price requirements; failure to comply could lead to delisting risks, further impacting the company's ability to raise funds and operate effectively.
See More
Biotech Sector Regulatory Approvals and Collaborations
- Kidney Cancer Treatment Breakthrough: HUTCHMED and Innovent received NMPA approval in China for the ELUNATE-TYVYT combination therapy, supported by the FRUSICA-2 study showing a 63% reduction in disease progression or death risk, with a median progression-free survival of 22.2 months, significantly improving patient outcomes and enhancing market competitiveness.
- Antibiotic Market Expansion: Sunshine Biopharma received Canadian approval for its generic Amoxicillin, with shipments expected to begin in August 2026, aiming to increase access to high-quality antibiotics for treating common infections, which is anticipated to drive revenue growth for the company.
- Liquid Biopsy Technology Innovation: Guardant Health gained FDA approval for Guardant360 Liquid CDx, now the largest liquid biopsy panel with a genomic footprint 100 times broader than its predecessor, enhancing tumor profiling capabilities and expected to boost the company's market share in precision medicine.
- New Hypertension Drug Launch: AstraZeneca received FDA approval for BAXFENDY for hypertension patients, based on positive results from the BaxHTN Phase III trial, which is expected to strengthen the company's competitive position in the cardiovascular drug market and further expand its product line.
See More
Multiple Companies Experience Significant Stock Price Gains
- CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw a 55% increase in stock price, closing at $3.71, following the completion of its assay development strategy for the Bundibugyo virus, enhancing its market position in the Congo and Uganda.
- AKTX Breakthrough Clinical Data: Akari Therapeutics Plc (AKTX) rose nearly 50% to $5.14 after demonstrating synergistic activity of AKTX-101 with Adagrasib in KRAS-mutated pancreatic cancer models, with a Phase 1 clinical trial expected to start by mid-2027.
- P3 Health Financial Recovery: P3 Health Partners Inc. (PIII) gained over 40%, closing at $13.86, reporting a net income of $3 million for Q1, a significant turnaround from a $44.2 million loss last year, with full-year revenue projected between $1.5 billion and $1.65 billion.
- Sunshine Drug Approval: Sunshine Biopharma Inc. (SBFM) jumped over 40% to $0.51 after receiving approval for its generic Amoxicillin in Canada, expected to ship by August 2026, further expanding its market share.
See More
Sunshine Biopharma Raises $6 Million in Public Offering
- Financing Structure: Sunshine Biopharma has priced a public offering of 12 million common units at $0.50 each, raising a total of $6 million, with closing expected on May 19, 2026, thereby strengthening its cash position for future growth.
- Shareholder Rights: Each common unit consists of one share of common stock and two Series C warrants, which are exercisable immediately at $0.50 per share for five years, enhancing potential returns for investors.
- Market Performance: The company's stock surged 79.51% in yesterday's trading to close at $0.51, although it fell 5.57% in after-hours trading, reflecting a positive market reaction to the new financing amid short-term volatility.
- Product Expansion: Sunshine currently markets 60 generic prescription drugs in Canada and plans to launch 12 additional products in 2026, while also advancing two proprietary drug programs aimed at expanding its footprint in oncology and antiviral therapeutics.
See More
